Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval

Executive Summary

Clinical trial diversity, FDA hiring authority, and inactive ingredient disclosure provisions all get slight modifications. The bill glides through committee, but not without some complaints about agency performance.

You may also be interested in...



PDUFA Collections Exceeded Target In FY 2021, While GDUFA Fell Short

The US FDA reports that the prescription drug user fee program met 27 of its 29 commitments by the end of FY 2021 and the biosimilar user fee program is on track to meet 16 of 27 of its performance enhancement goals.

Cosmetics Industry Stakeholders Not Thrilled About Senate Reform Bill, And Why Should They Be?

In HBW Insight’s conversations with industry advocates about legislation in the US Senate to reform US cosmetics regulations, frustrations with the process have been palpable. Stakeholders suggest that science and proportionality are taking back seats to politics and that concerns about costs to industry, which ultimately could be passed on to consumers, are not being taken seriously enough.

Therapeutic Equivalence Evaluations Would Be Required For 505(b)(2) Drugs Under Senate User Fee Bill

The Senate HELP Committee added a therapeutic equivalence provision to the draft measure it floated two weeks ago. The bill introduced in the Senate still does not include provisions on clinical trial diversity or 180-day exclusivity.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS146198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel